Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q4 2024 ▲▼ | Q1 2025 ▲▼ | Change ▲▼ | Q4 2024 ▲▼ | Q1 2025 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| Newamsterdam Pharma Company ORDINARY SHARES | 10,597,181 | 10,935,310 | +338,129 | $272.35M | $223.85M | 54.11% | -$48.50M |
| Dyne Therapeutics, Inc.(DYN) | 5,462,846 | 5,462,846 | 0 | $128.70M | $57.14M | 13.81% | -$71.56M |
| Engene Holdings Inc COM | 9,632,561 | 9,632,561 | 0 | $64.06M | $43.15M | 10.43% | -$20.90M |
| Replimune Group, Inc.(REPL) | 3,970,668 | 3,909,696 | -60,972 | $48.08M | $38.12M | 9.21% | -$9.97M |
| Bicycle Therapeutics PlcADS | 3,452,330 | 3,452,330 | 0 | $48.33M | $29.31M | 7.08% | -$19.02M |
| Astria Therapeutics Inc | 2,872,537 | 3,822,537 | +950,000 | $25.68M | $20.41M | 4.93% | -$5.27M |
| Engene Holdings IncW EXP 10 31 2028 *W EXP 10/31/202 | 2,878,148 | 2,878,148 | 0 | $2.43M | $1.73M | 0.42% | -$699.1K |
| Achilles Therapeutics PlcADS | 2,390,050 | 0 | -2,390,050 | $2.75M | $0 | — | -$2.75M |